Section 3.2.1.1 SSRI Adverse Reactions Tables

SSRI Adverse Reactions Table 1

SSRI Adverse Reactions (%)(Greater than 1% in at least on agent)
Citalopran Fuoxetine Fluvoxanine Paroxetire Regular Paroxeline Cr Sertraline
Miscellaneous
headache - 21 22 18 27 26
asthenia - 12 14 14-22 14 >/=1
fever 2 2 - - >/=1
Allergy allergic reaction - 1.2 0.1-1 0.1-1 2 <0.1
flu syndrome - 5 3 - 8 -
chills - >/=1 2 2 - 1.6
back pain - 2 - 3 5 >/=1
accidental injury - 4 >/=1 - 5 -
Malaise - 0.1-1 >/=1 >/=1 - >/=1
Weight Loss >/=1 2 >/=1 >/=1 - 0.1-1
Weight Gain >/=1 >/=1 >/=1 >/=1 - >/=1
Edena 0.1-1 - >/=1 >/=1 - 0.1-1
Cardiovascular
Palpitations - 2 3 2-3 - >/=1
Hot Flashes 0.1-1 - - - - 2
Vasodilation - 3 3 3.4 2 -
Hypotension(Postural) >/=1 - >/=1 - - 0.1-1
Hypertension 0.1-1 >/=1 >/=1 >/=1 - 0.1-1
Syncope - - >/=1 >/=1 - 0.1-1
Tacycaidia >/=1 - >/=1 >/=1 1 0.1-1
Chest Pain - 1.3 - 3 - >/=1

CNS

Insomnia 15 20 21 19-24 17 16-28
Somnolence 18 13 22 19-24 22 13-15
Nervousness - 13 12 6-9 - 6
Anxiety 4 13 5 5 - 4
Dizziness - 10 11 12-14 14 13
Tremor 3 10 5 8-11 7 5-11
Depression >/=1 - 2 >/=1 >/=1 0.11
Libido decreased 2 4 2 3-9 7 1-11
Myocinus/Twitching - 0.1-1 >/=1 3 - 0.1-1
Agitator 3 >/=1 2 5 2 6
Parasthesia >/=1 - - 4 3 3
hypertoria 0.1-1 0.1-1 2 - 3 >/=1
CNS stimulation - 0.1-1 2 >/=1 - -
confusion >/=1 >/=1 - 1 1 0.11
fatigue 5 - - - - 12
Concentration, decreased >/=1 - - 3 0.1-1 -
Drugged feeling - - - 2 - -
Amnesia >/=1 >/=1 >/=1 2 0.1-1 0.1-1
Emotional stability 0.1-1 >/=1 0.1-1 >/=1 0.1-1 0.1-1
Vertigo 0.1-1 - 0.1-1 >/=1 0.1-1 0.1-1
Hypoesthesia 0.1-1 - - - - >/=1
Apathy >/=1 - >/=1 - - 0.1-1
Hypo/Hyperkenesia 10.1-1 - >/=1 - - 0.1-1
Manic reaction - - >/=1 - - -
Psychotic reaction - - >/=1 - - -
Abnormal dreams - 5 - 4 - 0.1-1
Abnormal thinking - 4 - 0.1-1 0.1-1 -
sleep disorder - >/=1 0.1-1 - - -
depersonalization 01.1-1 0.1-1 0.1-1 3 - 3

SSRI Adverse Reactions Table 2

SSRI Adverse Reactions (%) (Greater than 1% in at least one agent)
Citalopram Fluoxetine Fluvoxamine Paroxetine regular Paroxetine CR Sertraline

GI

Nasea 21 23 40 23-26 22 26-30
Vomiting 4 3 5 - 2 4
Decreased appetite - - - 6-9 4 -
Diarrhea/loose stoools 8 12 11 10-12 18 18-24
Dyspepsia 5 8 10 2 - 6-10
Dry Mouth 10 10 14 10 15 15
Anorexia 4 11 6 6 - 3-11
Constipation - 4.5 10 8-16 10 6-8
Abdominal pain 3 3.1 - 4 7 -
Flatulence >/=1 3 4 4 6 3
Gastroenteritis 0.1-1 0.1-1 0.1-1 0.1-1 - 0.1-1
Increased appetite 0.1-1 >/=1 - 2-4 - >/=1
Tooth disorder/caries - - 3 <0.1 - 0.1-1
oropharynx disorder - - - 2 - -
Dysphagia 0.1-1 0.1-1 2 0.1-1 - 0.1-1
Melena - 2 - - - <0.1

Muscolo skeletal

Myaglia 2 5 - 2 1 >/=1
Myasthenia - <0.1 - 1 0.1-1 -
Moypathy - <0.1 - 2 - -
Arthralgia 2 - 0.1-1 >/=1 2 0.1-1

Respiratory

Upper Respiratory infection 5 - 9 - - 0.1-1
Pharyngitis - 5 - - - -
Sinusitis 3 - >/=1 - - 0.1-1
Cough (increased) >/=1 - >/=1 - - 0.1-1
Dyspnea 0.1-1 - 2 - - 0.1-1
Bronchitis 0.1-1 - 0.1-1 - 1 <0.1
Khinitis 5 - - 3 4 >/=1
Yawn 2 - 2 4 5 >/=1

Dermatologic

Sweating, excessive 11 8 7 9-14 6 5-8
rash >/=1 4 - 3 - 23
Pruritis >/=1 3 - >/=1 0.1-1 0.1-1
Acne 0.1-1 0.1-1 0.1-1 0.1-1 0.1-1 0.1-1

Special Senses

Vision Disturbances/Blurred Vision >/=1 3 - 4 5 4
Taste Perversion/change >/=1 >/=1 0 2 2 0
Tinnitus 0.1-1 >/=1 - >/=1 - >/=1
Amblyopia - - 3 0 0 0

GU

Sexual dysfunction/impotence

/anorgasmia

3 - 2 5-8 5 >/=1
Urinary frequency - >/=1 3 2-3 - 2
Urinary tract infection - - 0.1-1 2 3 -
Abnormal ejaculation 6 - 8 21-23 26 7-19
Male genital disorder, other - - - 10 - -
Urinary disorder/retention 0.1-1 0.1-1 1 3 - 0.1-1
Female genital disorders - - - 2-9 10 -
menstrual disorder 3 - 0.1-1 - 2 0.1-1

Adaptation to certain adverse events: Over a 4-6 week period, there was evidence of adaptation to some adverse events with continued therapy (e.g. nausea, dizziness), but less to other effects (e.g. dry mouth, somnolence, asthenia).

Reference: Facts and Comparisons Jan. 2000